<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112749</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000428460</org_study_id>
    <secondary_id>UCLA-0410033-01</secondary_id>
    <nct_id>NCT00112749</nct_id>
  </id_info>
  <brief_title>Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer</brief_title>
  <official_title>Does Blocking Proinflammatory Cytokines Diminish Cancer-Related Fatigue?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Cancer Society, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Infliximab may help improve energy levels in patients who have undergone treatment&#xD;
      for breast cancer.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well infliximab works in treating cancer-related&#xD;
      fatigue in postmenopausal women who have undergone treatment for stage 0, stage I, or stage&#xD;
      II breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the association between the body's immune system and energy, sleep, mood, and&#xD;
           other symptoms in postmenopausal women who have undergone treatment for stage 0-II&#xD;
           breast cancer.&#xD;
&#xD;
        -  Determine whether treatment with infliximab affects energy and immune function in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: Patients receive infliximab IV over 2 hours.&#xD;
&#xD;
      Patients complete a diary twice daily for 14 days before and for 14 days after infliximab&#xD;
      administration to assess fatigue and other symptoms, including mood, pain, and sleep.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 2 weeks and then monthly for 3&#xD;
      months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment stopped due to slow accrual and lack of evidence of need for further continuation&#xD;
    of protocol in inpatient setting.&#xD;
  </why_stopped>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in fatigue as measured by the fatigue symptom inventory (FSI)</measure>
    <time_frame>At baseline and after completion of study treatment, 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in fatigue as measured by multidimensional fatigue symptom inventory (MFSI)</measure>
    <time_frame>At baseline and after completion of study treatment, 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in proinflammatory cytokines as measured by interleukin-1 receptor antagonist value</measure>
    <time_frame>At baseline and after completion of study treatment, 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proinflammatory cytokines as measured by interleukin 6 value</measure>
    <time_frame>At baseline and after completion of study treatment, 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proinflammatory cytokines as measured by tumor necrosis factor</measure>
    <time_frame>At baseline and after completion of study treatment, 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Please see intervention description</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>infliximab</intervention_name>
    <description>A single infusion of 1mg/kg will be administered.</description>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical Assessment</intervention_name>
    <description>Medical, psychiatric, and immune evaluation.</description>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Self-report questionnaires</intervention_name>
    <description>Fatigue Symptom Inventory, Multidimensional Fatigue Symptom Inventory, Hamilton Depression Rating Scale, Beck Depression Inventory II, Hamilton anxiety Rating Scale, Pittsburgh Sleep Quality Index, Brief Pain Inventory, MOS SF-36.</description>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immune Assessment</intervention_name>
    <description>Proinflammatory cytokines and markers of cytokine activity and lymphocyte subsets and CBC.</description>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women who report elevated fatigue following cancer diagnosis and treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who have medical conditions that may affect the immune system or are associated&#xD;
             with baseline fatigue syndrome, and/or who use medications that affect the immune&#xD;
             system or fatigue.&#xD;
&#xD;
          -  Women with major affective disorders and those with sleep or pain disorders.&#xD;
&#xD;
          -  Presence of medical conditions that may but subject at undue risk for experimental&#xD;
             procedures.&#xD;
&#xD;
          -  Chronic or recurring infections, symptoms of chronic heart failure, demyelinating&#xD;
             disorders, and those taking immunosuppressive medications.&#xD;
&#xD;
          -  Neoplastic disease other than primary breast cancer&#xD;
&#xD;
          -  Compromised cardiovascular function&#xD;
&#xD;
          -  Insulin-dependent diabetes&#xD;
&#xD;
          -  Neurological disorder&#xD;
&#xD;
          -  Peripheral neuropathy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Use of psychotropic medications within 2 weeks of screening&#xD;
&#xD;
          -  Abnormal screening laboratory findings (i.e., creatinine &gt; 1.4mg%; anemia; abnormal&#xD;
             thyroid hormone; hematuria; elevated liver function tests, low protein or albumin;&#xD;
             fasting glucose &gt;120mg%; elevated FTI or TSH; positive TB screening, HIV screening or&#xD;
             hepatitis C).&#xD;
&#xD;
          -  Smokers&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia A. Ganz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>June 2, 2005</study_first_submitted>
  <study_first_submitted_qc>June 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2005</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>breast cancer in situ</keyword>
  <keyword>fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

